Ensysce Faces New Nasdaq Issue as Deadline Nears
NEW YORK, May 26, 2026, 08:04 EDT Ensysce Biosciences shares slipped in pre-market trading Tuesday. The clinical-stage drug maker said Nasdaq sent it a warning on a possible delisting if it does not outline a plan to address its stockholders’ equity deficit. Nasdaq gave Ensysce until July 6 to send a compliance plan, according to a Friday filing posted before U.S. markets closed for Memorial Day. The notice says stockholders’ equity is what remains for shareholders after assets minus liabilities. The rule in the notice calls for at least $2.5 million in equity. Ensysce is trading deep under $1, which